Hypertriglyceridemia News and Research

RSS

Hypertriglyceridemia refers to the condition where there are high blood levels of triglycerides, the most abundant fatty molecule in most organisms. It has been associated with atherosclerosis, even in the absence of hypercholesterolemia (high cholesterol levels). It can also lead to pancreatitis in excessive concentrations.

Postmenopausal breast cancer survivors at greater risk for developing heart disease

Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.

19 Jun 2019

New molecule could help fight type 2 diabetes and non-alcoholic fatty liver disease

A new molecule -EPB-53-, could help fight type 2 diabetes and the non-alcoholic fatty liver disease, according to a new study led by the team of Manuel Vázquez-Carrera, from the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Center.

10 Apr 2019

Epigenetic link found between prenatal exposure to maternal smoking and offspring's cardio-metabolic health

According to new research, epigenetic changes found in the offspring exposed to maternal smoking during pregnancy or in current smokers are linked to smoking-related diseases in adulthood.

13 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Pancreatitis risk in minorities linked to alcohol, gallstones and high triglycerides

Pancreatitis in ethnic minorities is linked to very high levels of triglycerides and the risk is further increased by alcohol abuse and gallstones, according to a study published in the journal Endocrine Practice.

16 Apr 2018

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

20 Apr 2017

ULCA scientists discover how autoantibodies cause some cases of severe hypertriglyceridemia

People with hypertriglyceridemia often are told to change their diet and lose weight. But a high-fat diet isn't necessarily the cause for everyone with the condition.

6 Apr 2017

Low normalized grip strength linked to cardiometabolic diseases and disabilities in adults

A simple test to determine a person's grip strength may be a predictor of developing metabolic disorders in middle or older age, a new cross-continental study has found.

5 Apr 2017

Experimental lipid-lowering drug improves glucose control in diabetic patients

High triglycerides -- a type of fat, or lipid, in the blood -- increase the risk of heart disease and perhaps type 2 diabetes. For the first time, it has been shown that profoundly lowering triglycerides in diabetics improves their insulin sensitivity over time, which helps them maintain healthy glucose - blood sugar -- levels.

28 Jun 2016

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets.

30 Apr 2016

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

Blocking the expression of certain gene reduces excessive fat in patients

By blocking the expression of a certain gene in patients, University of Montreal researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their blood, even in various severe forms of hypertriglyceridemia and regardless of the base values or the treatment the patient usually receives.

30 Jul 2015

Infants born with mutation in PLVAP gene develop severe protein losing enteropathy

Newborn children born with a mutation in the Plasmalemma Vesicle Associated Protein (PLVAP) gene develop severe protein losing enteropathy, according to a case study1 published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

23 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.

18 Mar 2015

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.

3 Feb 2015

Upregulating heme-oxygenase with hemin helps improve pericardial adipocyte morphology, function

Scientists at the University of Saskatchewan College of Medicine, Department of Physiology, Saskatoon, Canada, led by Dr. Joseph Fomusi Ndisang have determined that upregulating heme-oxygenase with hemin improves pericardial adipocyte morphology and function.

27 Jan 2015

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.

5 Nov 2014